NIX - Profile

« Back to Dashboard

US Patents and Regulatory Information for NIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	NIX	permethrin	LOTION;TOPICAL	019435-001	Mar 31, 1986		DISCN	No	No
Medtech Products	NIX	permethrin	LOTION;TOPICAL	019918-001	May 2, 1990		OTC	Yes	Yes

Nix Permethrin Drug Market Dynamics and Financial Trajectory

Last updated: September 24, 2026

Nix is an over-the-counter lice-treatment brand centered on permethrin 1% creme rinse. Its commercial position is driven by brand recognition, retail distribution, low treatment cost, and the recurring incidence of head lice. Its financial trajectory cannot be measured through standalone revenue because Prestige Consumer Healthcare, the brand owner, does not separately report Nix sales. Nix has no meaningful current pharmaceutical exclusivity barrier: generic permethrin products, alternative OTC treatments, prescription pediculicides, and retailer private-label products constrain pricing.

What is Nix and who owns the brand?

Nix is a topical pediculicide used to treat head lice. The principal product is Nix Lice Killing Creme Rinse, containing permethrin 1%. The product is applied to the scalp and hair and is marketed through mass retailers, pharmacies, grocery stores, online channels, and institutional purchasing.

Prestige Consumer Healthcare owns Nix as part of its over-the-counter healthcare portfolio. Prestige acquired Insight Pharmaceuticals in 2016. The transaction added a group of established consumer-health brands, including Nix, to Prestige’s portfolio (Prestige Consumer Healthcare, 2016).

Attribute	Nix
Active ingredient	Permethrin 1%
Dosage form	Topical creme rinse
Primary indication	Head lice
Regulatory category	OTC lice treatment
Brand owner	Prestige Consumer Healthcare
Principal channel	Retail and e-commerce
Main competitors	Generic permethrin, pyrethrin products, ivermectin, spinosad, malathion, dimethicone and retailer brands
Primary commercial risk	Low switching costs and limited pricing power

Nix is a consumer-health product rather than a high-growth specialty pharmaceutical. Its revenue depends on household treatment cycles, seasonal outbreaks, brand visibility, and retailer shelf placement.

What is the FDA regulatory status of Nix?

Nix permethrin 1% is an FDA-recognized OTC lice-treatment product. The product is associated with FDA approval history under NDA 018848 and is marketed for the treatment of head lice infestation. The FDA labeling describes permethrin 1% as a topical treatment for head lice in adults and children two months of age and older, subject to product labeling and usage instructions (U.S. Food and Drug Administration, n.d.-a).

The regulatory profile has several commercial implications:

1. Consumers can purchase Nix without a prescription.
2. Physicians and pharmacists have many substitute products.
3. Regulatory exclusivity does not materially protect the brand.
4. Product availability and consumer trust matter more than clinical differentiation.

The CDC identifies permethrin lotion as an established treatment option but recognizes that lice resistance to pyrethroids can reduce treatment effectiveness in some settings (Centers for Disease Control and Prevention, 2024).

What patents protect Nix?

Nix does not have a commercially meaningful active-ingredient patent position. Permethrin is an old synthetic pyrethroid, and the core compound is long off patent. The original product and formulation patents associated with permethrin lice treatments have expired or no longer create a practical barrier to generic competition.

The current competitive position is based on:

• Brand recognition
• Retail distribution
• Packaging and consumer instructions
• Manufacturing know-how
• Quality-control systems
• Marketing investment
• Retailer relationships

The FDA Orange Book does not provide Nix with the type of current patent-based protection associated with innovative prescription drugs. No material Orange Book-listed patent barrier is generally associated with the commercial sale of generic permethrin 1% products (U.S. Food and Drug Administration, n.d.-b).

Are there formulation patents for Nix?

Any formulation protection associated with older permethrin products has limited commercial value today. A topical permethrin product may still be protected by confidential manufacturing processes, supplier relationships, trademarks, packaging, or trade dress. Those protections do not prevent competitors from selling therapeutically equivalent permethrin products.

A formulation patent would need to cover a commercially important feature, such as improved stability, delivery, tolerability, or efficacy, and remain enforceable in the relevant jurisdiction. Publicly available product information does not establish that Nix has a current, blocking formulation patent estate.

Are there method-of-use patents for Nix?

Nix’s primary use, treating head lice with permethrin 1%, is an established therapeutic use. No significant current method-of-use exclusivity is evident from the public regulatory profile. The product therefore faces competition based on the same indication rather than relying on a protected new use.

When does Nix lose exclusivity?

Nix has already lost traditional pharmaceutical exclusivity. The relevant loss occurred through the expiration of the underlying compound and product protections, followed by the availability of generic and alternative lice treatments.

Exclusivity category	Nix status
New chemical entity exclusivity	Expired or not applicable
Active-ingredient patent	Expired
Core formulation protection	Expired, unavailable or commercially nonblocking
Current Orange Book patent barrier	No material barrier identified
OTC monograph protection	Does not create brand exclusivity
Trademark protection	Continues for the Nix name and branding
Retail distribution advantage	Potentially durable but not legally exclusive

Brand protection remains through trademarks and consumer recognition. A competing company can sell permethrin 1% treatment but cannot market it under the Nix name or copy protected branding.

How many competitors does Nix face?

Nix competes across three categories: equivalent permethrin products, alternative OTC pediculicides, and prescription treatments.

Generic and private-label permethrin

Generic permethrin 1% products are the closest substitutes. They can compete on price and are commonly available through pharmacies, online retailers, and store brands. Their presence limits Nix’s ability to raise prices without losing volume.

Alternative OTC products

Nix also competes with pyrethrin and piperonyl butoxide products, including RID-type treatments, as well as products using nontraditional physical mechanisms such as dimethicone. Parents and pharmacists may switch products after an initial treatment fails or when resistance is suspected.

Prescription products

Prescription alternatives include ivermectin lotion, spinosad topical suspension, malathion lotion, and topical or oral ivermectin in appropriate clinical circumstances. These products tend to have higher prices but can gain share when OTC therapy fails or when resistance concerns affect treatment selection.

The commercial threat is therefore broader than generic substitution. Nix competes against an entire treatment class with different mechanisms, price points, and prescription requirements.

What market dynamics affect Nix sales?

Seasonal demand

Head lice demand is episodic and often rises when children return to school, summer camps begin, or household transmission occurs. This creates a seasonal sales pattern rather than a steady chronic-treatment market.

Low treatment frequency

Most households purchase lice treatment only when an infestation occurs. Repeat purchases can occur because of reinfestation, household spread, incomplete treatment, or failure to remove eggs. The category has recurring demand, but individual-customer frequency is low.

Resistance pressure

Permethrin belongs to the pyrethroid class. CDC guidance indicates that resistance can affect treatment outcomes in some geographic areas. Resistance creates a direct risk to Nix because consumers may move to a different active ingredient after one unsuccessful treatment (Centers for Disease Control and Prevention, 2024).

Retail visibility

Nix benefits from placement in pharmacy and family-health sections. Online search ranking, retailer promotions, package clarity, and pharmacist recommendations can materially influence sales because products are often purchased urgently.

Pricing pressure

Permethrin products are relatively easy for consumers to compare. Generic and private-label products can undercut branded Nix. Prestige’s ability to defend revenue depends on maintaining a price premium that consumers associate with efficacy, safety, convenience, and brand familiarity.

What is the financial trajectory of Nix?

Nix revenue is not separately disclosed in Prestige Consumer Healthcare’s public filings. Prestige reports consolidated and portfolio-level results rather than brand-level sales for Nix. As a result, no verified public time series exists for Nix revenue, gross margin, operating profit, or market share.

Prestige’s financial model provides the relevant context:

Financial driver	Effect on Nix
Portfolio scale	Reduces dependence on any single OTC brand
Retail distribution	Supports broad availability
Advertising expense	Necessary to sustain brand awareness
Input costs	Can pressure gross margin
Retailer bargaining power	Can increase promotional and trade-spending demands
Generic competition	Limits price increases
Seasonal demand	Creates quarter-to-quarter volatility
Brand acquisition model	Favors mature cash-generating products over high-growth innovation

Prestige acquired established consumer-health brands to create a portfolio with repeat retail demand and relatively low research-and-development requirements. Nix fits that model. Its value is likely based on cash generation, distribution, and brand durability rather than patent-protected growth.

The likely financial trajectory is mature and defensive:

• Revenue growth depends mainly on category growth, price increases, distribution gains, and promotional execution.
• Unit volume is vulnerable to generic substitution and resistance-related switching.
• Gross margin can remain attractive because the product is topical, established, and sold through OTC channels.
• Marketing and retailer trade spending can increase when competitors discount aggressively.
• Product innovation is more likely to involve packaging, convenience, bundles, or adjacent lice-care products than a new molecular entity.

What generic launch risks exist for Nix?

Generic entry risk is high because the active ingredient is old, the product is OTC, and consumers can substitute across brands. A new generic or private-label product does not need to overcome a significant patent wall.

The most likely competitive effects are:

1. Retail price compression.
2. Reduced brand share in price-sensitive households.
3. Increased promotional spending.
4. Greater retailer leverage over shelf placement.
5. Lower consumer loyalty when product availability is limited.

The principal defense is brand equity. Nix can retain customers when consumers trust the name, want a familiar product, or purchase under time pressure. That defense is weaker when the competing product is materially cheaper and has the same active ingredient and concentration.

Which companies are challenging Nix?

Competition comes from branded and generic manufacturers rather than a single litigation challenger. The relevant competitors include:

• Perrigo and other generic OTC manufacturers
• Retailer-owned private-label suppliers
• Prestige’s branded OTC competitors
• Manufacturers of pyrethrin products
• Makers of dimethicone and other non-pyrethroid treatments
• Prescription-drug companies selling spinosad, ivermectin and malathion products

No material Nix-specific Paragraph IV challenge or patent settlement is identified in the cited public sources. That result is consistent with the product’s mature OTC status and limited patent exclusivity.

What patent litigation affects Nix?

No major current patent litigation involving Nix is identified in the cited public regulatory and company materials. Litigation risk is more likely to involve:

• Trademark infringement
• False or misleading advertising
• Product liability
• Packaging and labeling
• Retail distribution disputes
• Regulatory compliance

A patent suit is less likely to determine Nix’s commercial future than changes in category competition, product efficacy perceptions, resistance patterns, and retailer economics.

How strong is the Nix patent estate?

Nix has a weak pharmaceutical patent estate but a potentially durable consumer-brand position.

Protection layer	Strength
Active-ingredient patent	Weak or expired
Product patent	Weak or expired
Method-of-use protection	Weak
Regulatory exclusivity	None of material commercial significance
Trademark	Moderate to strong
Retail distribution	Moderate
Consumer recognition	Moderate to strong
Manufacturing know-how	Moderate but nonblocking

The brand can remain profitable after patent expiry because consumer-health products often monetize through familiarity and distribution. That model does not eliminate generic risk. It shifts the source of defensibility from legal exclusivity to execution.

What is the outlook for Nix revenue?

Nix is more likely to produce mature, fluctuating cash flow than sustained high growth. The principal upside factors are increased lice incidence, stronger retail distribution, effective digital marketing, product-line extensions, and successful premium positioning.

The principal downside factors are generic price competition, reduced pyrethroid effectiveness, retailer private-label expansion, consumer switching to non-pyrethroid treatments, and limited household purchase frequency.

Nix’s financial importance to Prestige is likely best evaluated as part of the company’s broader OTC Healthcare portfolio. Public filings do not support a standalone valuation or precise revenue forecast for Nix. The brand’s economic value is tied to its ability to preserve share and margin in a low-growth, highly substitutable category.

Key Takeaways

• Nix is an OTC permethrin 1% head-lice treatment owned by Prestige Consumer Healthcare.
• The product has no meaningful current compound or patent exclusivity.
• Generic permethrin, private-label products, alternative OTC treatments, and prescription pediculicides create substantial competitive pressure.
• Pyrethroid resistance is a direct commercial risk because treatment failure can drive consumers to competing active ingredients.
• Nix revenue and profit are not separately disclosed by Prestige.
• The brand’s value rests on trademark protection, distribution, consumer recognition, and retail execution.
• No material Nix-specific Paragraph IV litigation or patent settlement is identified in the cited sources.
• The likely financial profile is mature, seasonal, and cash-generative, with limited organic growth and significant price sensitivity.

FAQs

Is Nix the same as generic permethrin?

No. Nix is a branded product containing permethrin 1%. Generic products may contain the same active ingredient and concentration but are sold under different names and packaging.

Can a competitor launch a generic Nix product?

A competitor can launch a permethrin 1% product if it satisfies applicable FDA requirements. It cannot use the Nix trademark or copy protected branding and trade dress.

Is Nix covered by a current patent?

No material current patent barrier is identified for Nix’s active ingredient or primary use. Its commercial protection is primarily branding and distribution.

Does Nix have biosimilar risk?

No. Nix is a small-molecule topical product, not a biologic. Biosimilar competition is not relevant. Its principal exposure is generic and alternative-product competition.

Is Nix a high-growth pharmaceutical asset?

No. Nix is a mature OTC consumer-health brand. Its investment profile depends on stable demand, retail execution, margin management, and resistance to generic substitution rather than innovative-drug growth.

References

1. Centers for Disease Control and Prevention. (2024). Clinical care of head lice. https://www.cdc.gov/lice/hcp/clinical-care/index.html

2. Prestige Consumer Healthcare, Inc. (2016). Prestige Consumer Healthcare to acquire Insight Pharmaceuticals. Company press release.

3. Prestige Consumer Healthcare, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

4. U.S. Food and Drug Administration. (n.d.-a). Nix Lice Killing Creme Rinse, permethrin 1%: Product labeling and approval information. Drugs@FDA.

5. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. Orange Book.